Comparison between adjuvant chemotherapy and adjuvant radiotherapy/chemoradiotherapy after radical surgery in patients with cervical cancer: a meta-analysis

Abstract

ObjectiveTo estimate the effect of adjuvant chemotherapy (AC) on the prognosis in cervical cancer patients with intermediate- or high-risk factors after radical hysterectomy (RH) compared to that for adjuvant radiotherapy (AR).MethodsThe Embase and MEDLINE databases and the Cochrane Library were searched for published studies comparing cervical cancer patients who received AC with those who received AR after RH. The endpoints were patient oncologic outcome. Random-effects meta-analytical models were used to calculate the pooled estimates of the effect of AC on mortality/recurrence.ResultsTwo randomized trials and eleven observational studies (AC, 942 patients; AR, 1,721 patients) met our search criteria. There were no significant differences in mortality and any recurrence between two groups. The results for distant recurrence favored the AC group (pooled odds ratio: 0.69; 95% confidence interval: 0.54–0.88; p=0.03). In subgroup analyses (for study design, histology, indication for adjuvant treatment, AR type, AC type, and lymph node metastasis), there was no significant increase in mortality and recurrence for AC compared with that for AR.ConclusionCompared to AR, AC showed similar survival outcomes in cervical cancer patients undergoing RH and also appeared to reduce the risk of distant recurrence.

Long‐term oncological outcomes of minimally invasive radical hysterectomy for early‐stage cervical cancer: A retrospective, single‐institutional study in the wake of the LACC trial

“…However, the results of this analysis are encouraging, showing that the rates of recurrence were comparably lower than the LACC results and with adjuvant treatment in the vast majority with chemotherapy only, without additional radiotherapy; thus, locoregional tumor control could be attributed to surgery alone with low morbidity. A meta‐analysis showed that compared to adjuvant radiotherapy, adjuvant chemotherapy showed similar survival outcomes in cervical cancer patients undergoing radical hysterectomy and also appeared to reduce the risk of distant recurrence . The third is that because MIRH for early‐stage cervical cancer has been proactively performed in our hospital as first‐line therapy since 2000, the subjects included very few cases of open surgery, rendering the presentation of comparative data for MIRH and ORH not feasible.…”

Resveratrol suppresses the growth and metastatic potential of cervical cancer by inhibiting STAT3Tyr705 phosphorylation

“…The survival outcome of patients with cervical cancer receiving adjuvant chemotherapy and/ or adjuvant radiotherapy (chemoradiotherapy) after radical hysterectomy are similar, and the risk of distant recurrence is reduced. 1 Neoadjuvant chemotherapy followed by radical surgery also has a favorable prognosis for locally advanced cervical cancer. 2,3 The main chemotherapy regimens for this disease include platinum-based drugs and taxanes.…”

Resveratrol Suppresses the Growth and Metastatic Potential of Cervical Cancer through Inhibiting STAT3Tyr705 Phosphorylation

“…Cervical cancer is one of the most common malignant tumors in the world for woman. Adjuvant chemotherapy and adjuvant radiotherapy (chemoradiotherapy) after radical hysterectomy show similar survival outcomes in cervical cancer patients and also appear to reduce the risk of distant recurrence (1). Neoadjuvant chemotherapy followed by radical surgery also predicts a favorable prognosis for local advanced cervical cancer (2,3).…”